- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- Zanubrutinib
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 24
- States / cities
- Aurora, Colorado • Newark, Delaware • Fort Myers, Florida + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Ultrasound Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2029
- U.S. locations
- 5
- States / cities
- Bethesda, Maryland • Detroit, Michigan • Rochester, Minnesota + 2 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Tolebrutinib, Teriflunomide, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 974 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 18 more
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- BGB-16673, BGB-11417
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Interventions
- Nemtabrutinib
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Volunteer
- Interventions
- BIIB091, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Multiple Myeloma (MM)
- Interventions
- acalabrutinib
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- High Risk Smoldering Multiple Myeloma
- Interventions
- Ibrutinib
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 13
- States / cities
- Duarte, California • Orange, California • Palo Alto, California + 10 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Pirtobrutinib, Obinutuzumab
- Drug
- Lead sponsor
- Inhye Ahn
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 4
- States / cities
- Scarborough, Maine • Boston, Massachusetts
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 899 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 43
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Arcadia, California + 38 more
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- BTK inhibitor PCI-32765, rituximab, bendamustine hydrochloride, pharmacogenomic studies, pharmacological study, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Kami Maddocks, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Bioavailability, B-cell Lymphoid Cancer
- Interventions
- Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell
- Interventions
- ABT-199 and Ibrutinib Combination
- Drug
- Lead sponsor
- Craig Portell, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 4
- States / cities
- Duarte, California • Atlanta, Georgia • St Louis, Missouri + 1 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
- Drug
- Lead sponsor
- Loxo Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 46
- States / cities
- Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 41 more
- Conditions
- Lymphoma, Mantle Cell
- Interventions
- Acalabrutinib, Bendamustine, Rituximab, Placebo
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Downey, California • Santa Monica, California + 27 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- SAR442168, Placebo, Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 9
- States / cities
- Cullman, Alabama • Maitland, Florida • Sunrise, Florida + 6 more
- Conditions
- Primary Immune Deficiency
- Interventions
- IgPro20
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 2 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 4
- States / cities
- Centennial, Colorado • North Palm Beach, Florida • Indianapolis, Indiana + 1 more
- Conditions
- Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- ofatumumab, ibrutinib
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 25
- States / cities
- La Jolla, California • Los Angeles, California • Santa Maria, California + 20 more
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Tafasitamab, Idelalisib, Venetoclax
- Biological · Drug
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Rochester, Minnesota • Columbus, Ohio
- Conditions
- Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion
- Interventions
- Ibrutinib
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Duarte, California • Greenbrae, California + 15 more
- Conditions
- Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Interventions
- Selinexor, Ibrutinib, Pharmacological Study, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Jennifer Woyach
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Salt Lake City, Utah
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- NX-5948
- Drug
- Lead sponsor
- Nurix Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 25
- States / cities
- Duarte, California • Los Angeles, California • San Diego, California + 21 more